This CPB has been revised to state that: (i) plasmapheresis (PP), plasma exchange (PE), or therapeutic apheresis is considered medically necessary for the treatment of mantle cell lymphoma (mantle cell leukemia) if white blood cells count is greater than 100,000/µL; and (ii) PP/PE or therapeutic apheresis is considered experimental and investigational for the treatment of hemoglobin Buenos Aires, and urticarial vasculitis.